

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Gurwitz, Jerry

eRA COMMONS USER NAME (credential, e.g., agency login): gurwitzj

POSITION TITLE: Professor of Medicine

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	Completion Date MM/YYYY	FIELD OF STUDY
Dartmouth College, Hanover, MA	AB	06/1978	Biology
University of Massachusetts Medical School, Worcester, MA	MD	06/1983	Medicine

A. Personal Statement

Jerry H. Gurwitz, MD is an academic geriatrician with extensive experience in cardiovascular, clinical epidemiologic, patient safety, and health information technology research relevant to older adults. Dr. Gurwitz serves as Executive Director of the Meyers Health Care Institute of Worcester, Massachusetts (a member of the Health Care Systems Research Network), which is a joint endeavor of Fallon Community Health Plan and the University of Massachusetts Medical School. He holds the Dr. John Meyers Professorship in Primary Care Medicine at the University of Massachusetts Medical School, where he also serves as Chief of the Division of Geriatric Medicine. Dr. Gurwitz has served as the Chair of the Governing Board and as a member of the Executive Committee of the Health Care Systems Research Network, a leading organization of health care delivery scientists. Dr. Gurwitz has also served as co-director of the NHLBI-funded Cardiovascular Research Network, and as a member of the FDA Sentinel Scientific Safety Committee. He is the PI of an R33 grant entitled Advancing Geriatrics Infrastructure and Network Growth ("AGING"), a collaborative endeavor of the Health Care Systems Research Network and the Older Americans Independence Centers focused on advancing the science of multiple chronic conditions in older adults.

Ongoing and recently completed projects that I would like to highlight include:

U54 AG063546, NIA
Mor/Mitchell (PI), Role: Executive Committee Member
09/01/19-06/30/24
NIA AD/DRD Health Care Systems Research Collaboratory

D43 TW011394, NIH
Dao/Allison (PI), Role: Co-Investigator
09/15/19-05/31/24
Training Program for Strengthening Research Capacity in Non-Communicable Diseases in Vietnam

R33 AG057806, NIA
Role: Principal Investigator
09/01/18 - 08/31/23
Advancing Geriatrics Infrastructure and Network Growth (AGING) Initiative

R01 HS026215, AHRQ
Herzig (PI), Role: Co-Investigator
07/01/19 - 06/30/23
Characterizing Opioid-Related Adverse Events in Older Adults after Hospital Discharge

R01 AG062630, NIA
Tisminetzky (PI), Role: Co-Investigator
09/15/19 - 06/30/23
Multimorbidity and Treatment-Related Outcomes in Older Heart Failure Patients

R33 AG057806, NIA
Role: Principal Investigator
06/15/19 - 04/30/23
Advancing Geriatrics Infrastructure and Network Growth (AGING) Initiative-Supplement

U01 AG034661, NIA
Go (PI), Role: Co-Investigator
07/01/15 - 03/31/22
PACTTE-Partnership for Anemia: Clinical and Translational Trials in the Elderly

R33 AG057806, NIA
Role: Principal Investigator
05/01/20-04/30/23
Advancing Geriatrics Infrastructure and Network Growth (AGING) Initiative- Covid-19 Supplement

B. Positions, Scientific Appointments, and Honors

Positions

2010 -	Professor of Quantitative Health Sciences, University of Massachusetts Medical School
2003 -	Chief of Division of Geriatric Medicine, University of Massachusetts Medical School
2003 -	Professor, University of Massachusetts Graduate School of Biomedical Sciences, Program in Clinical and Population Health Research
2000 -	Professor of Family Medicine and Community Health, University of Massachusett Medical School
1999 -	Professor of Medicine, University of Massachusetts Medical School
1996 -	The Dr. John Meyers Chair in Primary Care Medicine, University of Massachusetts Medical School
1996 - 2009	Lecturer on Ambulatory Care and Prevention, Harvard Medical School
1996 - 1999	Associate Professor of Medicine, University of Massachusetts Medical School
1993 - 1996	Assistant Professor of Medicine, Harvard Medical School
1988 - 1993	Instructor in Medicine, Harvard Medical School

Scientific Appointments

2015 - 2016	Chair, Health Care Systems Research Network (Formerly HMORN) Governing Board
2012 - 2016	Chair, American Geriatrics Society Research Committee
2012 - 2016	Executive Committee, Heath Care Systems Research Network Governing Board
2012 - 2014	Vice Chair, Health Care Systems Research Network (Formerly HMORN) Governing Board
2010 - 2016	Co-Director T2 & T3 (Bedside to Patients & Community), UMass Center for Clinical and Translational Science Steering Committee
1997 - 2001	Member, Agency for Healthcare Research and Quality Study Section-Health Care Quality and Effectiveness Research
1996 -	Executive Director, The Meyers Primary Care Institute (University of Massachusetts Medical School, Reliant Medical Group, Fallon Health)

1990 - 1996 Assistant Director, Harvard Geriatric Education Center
1988 - 1991 Fellow in Geriatric Clinical Pharmacology, Merck Foundation, Harvard Medical School
1987 - 1988 Fellow, Charles A. Dana Foundation

Honors

2013 Award for Outstanding Excellence in Geriatrics Research: Best Paper Award for All Categories – 2013 Annual Scientific Meeting, American Geriatrics Society
2009 Senior Geriatrics Leadership Scholar Award, John A. Hartford Foundation
2006 John Eisenberg Patient Safety and Quality Award for Research Achievement, National Quality Forum
2004 George F. Archambault Award, American Society of Consultant Pharmacists
2004 Member, Institute of Medicine Committee on Identifying and Preventing Medication Errors
2001 William B. Abrams Award in Geriatric Clinical Pharmacology, American Society for Clinical Pharmacology and Therapeutics
1996 Leon I. Goldberg Young Investigator Award, American Society for Clinical Pharmacology and Therapeutics
1994 Fellow, Gerontological Society of America
1994 Fellow, American Geriatrics Society
1994 Fellow, American College of Physicians

C. Contributions to Science

1. Cardiovascular Disease in Older Adults: Dr. Gurwitz has published extensively on the topics relevant to the health and healthcare of older adults with cardiovascular disease. He has examined issues relating to the exclusion of older adults from clinical trials of treatments for cardiovascular disease, the clinical characteristics of older adults with heart failure and acute myocardial infarction, and the comparative effectiveness and safety of drug therapies and other interventions in the care of patients with heart disease.
 - a. Go AS, Yang J, **Gurwitz JH**, Hsu J, Lane K, Platt R. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure. *Am J Cardiol.* 2007 Aug 15;100(4):690-6. PMID: 17697830.
 - b. **Gurwitz JH**, Magid DJ, Smith DH, Goldberg RJ, McManus DD, Allen LA, Saczynski JS, Thorp ML, Hsu G, Sung SH, Go AS. Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. *Am J Med.* 2013 May;126(5):393-400. PMID: PMC3627730.
 - c. Singh S, Zieman S, Go AS, Fortmann SP, Wenger NK, Fleg JL, Radziszewska B, Stone NJ, Zoungas S, **Gurwitz JH**. Statins for primary prevention in older adults-moving toward evidence-based decision-making. *J Am Geriatr Soc.* 2018; 66:2188-2196. PMID: PMC6741349.
 - d. **Gurwitz JH**, Maurer MS. Tafamidis- a pricey therapy for a not-so-rare condition. *JAMA Cardiol.* 2020; 5(3): 247-248. PMID:31913401.
2. Multiple Chronic Conditions (MCCs) and Older Adults: Dr. Gurwitz has published extensively on the topic of multimorbidity in older adults. He has led studies using innovative observational methods to examine treatment effectiveness in patients with important and prevalent comorbidity dyads who have traditionally been excluded from participation in clinical trials, led an effort to identify research priorities relevant to improving the health and healthcare of older adults with MCCs, and advocated for the inclusion of patients with MCCs in large simple trials of primary prevention (e.g., a primary prevention statin trial in older adults).
 - a. **Gurwitz JH**, Go AS, Fortmann SP. Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence. *JAMA.* 2016 Nov 15;316(19):1971-1972. PMID: PMC5429025.
 - b. **Gurwitz JH**, Magid DJ, Smith DH, Tabada GH, Sung SH, Allen LA, McManus DD, Goldberg RJ, Tisminetzky M, Go AS. Treatment Effectiveness in Heart Failure with Comorbidity: Lung

Disease and Kidney Disease. *J Am Geriatr Soc.* 2017 Dec;65(12):2610-2618. PMID: PMC5729050.

- c. Tisminetzky M, Bayliss EA, Magaziner JS, Allore HG, Anzuoni K, Boyd CM, Gill TM, Go AS, Greenspan SL, Hanson LR, Hornbrook MC, Kitzman DW, Larson EB, Naylor MD, Shirley BE, Tai-Seale M, Teri L, Tinetti ME, Whitson HE, **Gurwitz JH**. Research Priorities to Advance the Health and Health Care of Older Adults with Multiple Chronic Conditions. *J Am Geriatr Soc.* 2017 Jul;65(7):1549-1553. PMID: PMC5507733.
 - d. Tisminetzky M, **Gurwitz J**, McManus DD, Saczynski JS, Erskine N, Waring ME, Anatchkova M, Awad H, Parish DC, Lessard D, Kiefe C, Goldberg R. Multiple Chronic Conditions and Psychosocial Limitations in Patients Hospitalized with an Acute Coronary Syndrome. *Am J Med.* 2016 Jun;129(6):608-14. PMID: PMC4879087.
3. Patient Safety: Dr. Gurwitz has studied the epidemiology of adverse drug events in the ambulatory and long-term care settings. His work has identified the incidence, types, severity, and preventability of medication-related injuries to older adults, and the types of errors that are most commonly associated with these injuries. He has also examined risk factors related to adverse drug events, and the high-risk period for older adults transitioning post-hospital discharge.
- a. **Gurwitz JH**, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. *JAMA.* 2003 Mar 5;289(9):1107-16. PMID: 12622580.
 - b. Field TS, **Gurwitz JH**, Harrold LR, Rothschild JM, Debellis K, Seger AC, Fish LS, Garber L, Kelleher M, Bates DW. Strategies for detecting adverse drug events among older persons in the ambulatory setting. *J Am Med Inform Assoc.* 2004 Nov-Dec;11(6):492-8. PMID: PMC524629.
 - c. Field TS, Mazor KM, Briesacher B, Debellis KR, **Gurwitz JH**. Adverse drug events resulting from patient errors in older adults. *J Am Geriatr Soc.* 2007 Feb;55(2):271-6. PMID: 17302666.
 - d. **Gurwitz JH**, Field TS, Radford MJ, Harrold LR, Becker R, Reed G, DeBellis K, Moldoff J, Verzier N. The safety of warfarin therapy in the nursing home setting. *Am J Med.* 2007 Jun;120(6):539-44. PMID: 17524757.
4. Health Information Technology: Dr. Gurwitz has led several studies to reduce the risk of adverse drug events employing computerized clinical decision support. He has also published on the use of health information technology-based interventions to reduce rehospitalizations as older patients transition from the hospital to the ambulatory setting. Of note, his efforts have also involved low-technology based interventions to improve medication safety including the use of the SBAR technique to standardize communication.
- a. Field TS, Rochon P, Lee M, Gavendo L, Subramanian S, Hoover S, Baril J, **Gurwitz J**. Costs associated with developing and implementing a computerized clinical decision support system for medication dosing for patients with renal insufficiency in the long-term care setting. *J Am Med Inform Assoc.* 2008 Jul-Aug;15(4):466-72. PMID: PMC2442257.
 - b. **Gurwitz JH**, Field TS, Rochon P, Judge J, Harrold LR, Bell CM, Lee M, White K, LaPrino J, Erramuspe-Mainard J, DeFlorio M, Gavendo L, Baril JL, Reed G, Bates DW. Effect of computerized provider order entry with clinical decision support on adverse drug events in the long-term care setting. *J Am Geriatr Soc.* 2008 Dec;56(12):2225-33. PMID: 19093922.
 - c. Field TS, Tjia J, Mazor KM, Donovan JL, Kanaan AO, Harrold LR, Reed G, Doherty P, Spenard A, **Gurwitz JH**. Randomized trial of a warfarin communication protocol for nursing homes: an SBAR-based approach. *Am J Med.* 2011 Feb;124(2): 179.e1-7. PMID: 21295198.
 - d. **Gurwitz JH**, Field TS, Ogarek J, Tjia J, Cutrona SL, Harrold LR, Gagne SJ, Preusse P, Donovan JL, Kanaan AO, Reed G, Garber L. An electronic health record-based intervention to increase follow-up office visits and decrease rehospitalization in older adults. *J Am Geriatr Soc.* 2014 May;62(5):665-71. PMID: PMC4351873.
5. Pharmacoepidemiology: Dr. Gurwitz has examined the risks of specific drug therapies employing large datasets. This work has focused on a range of drug classes including nonsteroidal anti-inflammatory drugs, thrombolytics, lipid lowering agents, and antipsychotic medications.

- a. **Gurwitz JH**, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. *JAMA*. 1994 Sep 14;272(10):781-6. PMID: 8078142.
- b. **Gurwitz JH**, Gore JM, Goldberg RJ, Barron HV, Breen T, Rundle AC, Sloan MA, French W, Rogers WJ. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. *Ann Intern Med*. 1998 Oct 15;129(8):597-604. PMID: 9786806.
- c. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, **Gurwitz JH**, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. *JAMA*. 2004 Dec 1;292(21):2585-90. PMID: 15572716.
- d. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, Bell CM, Lee PE, Fischer HD, Herrmann N, **Gurwitz JH**, Rochon PA. Antipsychotic drug use and mortality in older adults with dementia. *Ann Intern Med*. 2007 Jun 5;146(11):775-86. PMID: 17548409.

Complete List of Published Work in My Bibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/1F3ZxvhDsSR5K/bibliography/47015473/public/>